Uptake in the United States has been low, despite several authorised therapies and promising clinical trial results COVID-ANTIBODY I n the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19. But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why. Source: Nature.com/authentic news
Improve yourselves everyday